Gilead to face legal action on California marketing practices

15 February 2019

American charity AIDS Healthcare Foundation (AHF) has claimed victory in litigation against Gilead Sciences (Nasdaq: GILD), related to the firm’s promotion of its tenofovir disoproxil fumarate (TDF) based HIV/AIDS medications.

The cases allege that California-based patients were affected by the firm’s promotion of the TDF drug formulation, knowing a safer alternate, tenofovir alafenamide (TAF) product existed.

The Superior Court of California accepted only one of Gilead’s arguments in a demurrer seeking to have all the HIV/AIDS patients’ legal theories dismissed.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK